| Similar Articles |
|---|
 |
Chemistry World
April 13, 2015
Emma Stoye |
Generics giant Mylan offers $30 billion for Perrigo Generics manufacturer Mylan has made an unsolicited, public offer to buy Ireland-based rival Perrigo for $205 per share.   |
Chemistry World
December 8, 2015
Phillip Broadwith |
Perrigo nabs US rights to AZ Crohn's drug Irish drug maker Perrigo has fended off a hostile takeover bid from rival Mylan, and agreed to buy the US distribution rights to AstraZeneca's gastroenterology drug Entocort (budesonide). |
Chemistry World
May 1, 2015
Rebecca Trager |
Generics firms in three-way takeover battle US-based Mylan is gunning for Irish rival Perrigo, but the deal is overshadowed by a bid for Mylan itself from Israel's powerhouse Teva. |
Chemistry World
July 31, 2013
Daniel Johnson |
Perrigo bags Elan and its bargain Irish tax rates US drugmaker Perrigo has agreed to buy Irish pharma company Elan in a deal worth $8.6 billion. This hands Perrigo a base in low-tax Ireland and annual savings of up to $150 million in tax and operating costs. |
Chemistry World
November 11, 2014
Phillip Broadwith |
Perrigo to buy Omega Pharma for euro 3.6bn The former US-based Perrigo, which reincorporated in Ireland for tax reasons after buying Elan in 2013, will make use of Omega's established distribution networks in Europe to further expand its geographic reach. |
Chemistry World
April 22, 2015
Phillip Broadwith |
Daiichi Sankyo steps out after Sun-Ranbaxy merger Japanese firm Daiichi Sankyo has sold off its entire stake in India's Sun Pharmaceuticals, following Sun's takeover of Indian rival Ranbaxy, in which Daiichi was the controlling shareholder. |
Chemistry World
July 28, 2014
Andy Extance |
Takeover battle pushes Allergan to cut R&D jobs Despite a quarterly sales increase it describes as its strongest ever, Botox maker Allergan is laying off 1500 staff as it seeks to fend off a hostile takeover. |
Chemistry World
April 1, 2015
Sanjay Kumar |
Sun Pharma snares Ranbaxy in $4bn deal Sun Pharma is now the fifth largest generics drug company in the world. |
Chemistry World
June 13, 2008
Sarah Houlton |
Daiichi Sankyo makes bid for Ranbaxy The combination of the two companies - one focused on research and the other predominantly on generics - bucks the trend for research-based companies selling off or spinning out their generics businesses. |
The Motley Fool
June 26, 2006
Stephen D. Simpson |
Is Novartis the Future of Generics? Merck's recent pricing action might just be the beginning of the end of generics as we know them. Investors, take note. |
Chemistry World
November 24, 2014
Andy Extance |
Actavis rescues Allergan with $66 billion deal The acrimonious seven-month battle over the future of US biotech Allergan looks to be over, after the Botox-maker accepted a 'white knight' takeover bid from Actavis. |
The Motley Fool
July 21, 2011 |
Cabot Earnings Preview Cabot, a global specialty chemicals and performance materials company, will unveil its latest earnings on Tuesday. |
Pharmaceutical Executive
May 1, 2006
Joanna Breitstein |
Pharm Exec Q&A: Japanese Wedding Here, Daiichi Sankyo Pharma's John Alexander talks about the goals of its recent merger, the progress thus far, and shares insight into the development plans for its anti-platelet agent prasugrel. |
The Motley Fool
July 13, 2009
Brian Orelli |
Finally! It's a Win, Isn't It? Eli Lilly and marketing partner Daiichi Sankyo finally got a Food and Drug Administration approval of their blood thinner, Effient (prasugrel), on Friday afternoon. |
Chemistry World
January 11, 2010
Sean Milmo |
Evonik refocuses German chemicals, energy and real estate conglomerate Evonik Industries, is refocusing its operations on its chemical business in order to become a more powerful global player in the speciality chemicals arena. |
Pharmaceutical Executive
September 1, 2008
Sarah Houlton |
Doing More With Less In order to take a big step forward, GlaxoSmithKline looks to employ smaller licensing deals and business units. |
The Motley Fool
February 22, 2005
Rich Duprey |
Merger Mania Besets Japanese Pharmaceuticals A new law spurs megamergers in Japan's pharmaceutical industry. Stocks of companies seen as particularly interesting, including Eisai, Mitsubishi Pharma, and Shionogi, all jumped more than 2%. |
Chemistry World
July 29, 2015
Katrina Megget |
Allergan steps away from generics with sale to Teva In something of a surprise move, Allergan has committed to selling its generics business to Israeli generics giant Teva for $40.5 billion, despite having no prior plans to sell. |
